Moderna Cancer Vaccine Results Fall Short of Early Investor Hopes
Moderna’s personalized cancer vaccine showed promise in a study when added to immunotherapy, but the results did not meet investor expectations, according to the report.
Moderna’s personalized cancer vaccine showed promise in a study when added to immunotherapy, but the results did not meet investor expectations, according to the report.